These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

786 related articles for article (PubMed ID: 26408298)

  • 1. An overview of the NCI precision medicine trials-NCI MATCH and MPACT.
    Do K; O'Sullivan Coyne G; Chen AP
    Chin Clin Oncol; 2015 Sep; 4(3):31. PubMed ID: 26408298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Defining precision: The precision medicine initiative trials NCI-MPACT and NCI-MATCH.
    Coyne GO; Takebe N; Chen AP
    Curr Probl Cancer; 2017; 41(3):182-193. PubMed ID: 28372823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network.
    Abrams J; Conley B; Mooney M; Zwiebel J; Chen A; Welch JJ; Takebe N; Malik S; McShane L; Korn E; Williams M; Staudt L; Doroshow J
    Am Soc Clin Oncol Educ Book; 2014; ():71-6. PubMed ID: 24857062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NCI-MATCH launch highlights new trial design in precision-medicine era.
    McNeil C
    J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 26142446
    [No Abstract]   [Full Text] [Related]  

  • 5. Is the NCI MATCH trial a match for gynecologic oncology?
    Moore KN; Mannel RS
    Gynecol Oncol; 2016 Jan; 140(1):161-6. PubMed ID: 26586415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The NCI-MATCH trial and precision medicine in gynecologic cancers.
    Barroilhet L; Matulonis U
    Gynecol Oncol; 2018 Mar; 148(3):585-590. PubMed ID: 29366510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Perspectives on research activity in the USA on Cancer Precision Medicine.
    Bando H; Takebe N
    Jpn J Clin Oncol; 2016 Feb; 46(2):106-10. PubMed ID: 26531706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. National Cancer Institute Basket/Umbrella Clinical Trials: MATCH, LungMAP, and Beyond.
    Chen AP; Eljanne M; Harris L; Malik S; Seibel NL
    Cancer J; 2019; 25(4):272-281. PubMed ID: 31335391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. American Society of Clinical Oncology Developing First Clinical Trial.
    Brower V
    J Natl Cancer Inst; 2015 Nov; 107(11):djv356. PubMed ID: 26538625
    [No Abstract]   [Full Text] [Related]  

  • 10. National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH).
    Meric-Bernstam F; Ford JM; O'Dwyer PJ; Shapiro GI; McShane LM; Freidlin B; O'Cearbhaill RE; George S; Glade-Bender J; Lyman GH; Tricoli JV; Patton D; Hamilton SR; Gray RJ; Hawkins DS; Ramineni B; Flaherty KT; Grivas P; Yap TA; Berlin J; Doroshow JH; Harris LN; Moscow JA
    Clin Cancer Res; 2023 Apr; 29(8):1412-1422. PubMed ID: 36662819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Considerations of developing an NGS assay for clinical applications in precision oncology: The NCI-MATCH NGS assay experience.
    Lih CJ; Takebe N
    Curr Probl Cancer; 2017; 41(3):201-211. PubMed ID: 28625332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Initiative for Molecular Profiling and Advanced Cancer Therapy and challenges in the implementation of precision medicine.
    Tsimberidou AM
    Curr Probl Cancer; 2017; 41(3):176-181. PubMed ID: 28410846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Precision Oncology Medicine: The Clinical Relevance of Patient-Specific Biomarkers Used to Optimize Cancer Treatment.
    Schmidt KT; Chau CH; Price DK; Figg WD
    J Clin Pharmacol; 2016 Dec; 56(12):1484-1499. PubMed ID: 27197880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Precision medicine: A major step forward in specific situations, a myth in refractory cancers?].
    Albin N; Mc Leer A; Sakhri L
    Bull Cancer; 2018 Apr; 105(4):375-396. PubMed ID: 29501208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NCI-MATCH trial pushes cancer umbrella trial paradigm.
    Mullard A
    Nat Rev Drug Discov; 2015 Aug; 14(8):513-5. PubMed ID: 26228747
    [No Abstract]   [Full Text] [Related]  

  • 16. Exceptional Responders Inspire Change: Lessons for Drug Development From the Bedside to the Bench and Back.
    Chau NG; Lorch JH
    Oncologist; 2015 Jul; 20(7):699-701. PubMed ID: 26040619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The landscape of precision cancer medicine clinical trials in the United States.
    Roper N; Stensland KD; Hendricks R; Galsky MD
    Cancer Treat Rev; 2015 May; 41(5):385-90. PubMed ID: 25864024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What have we learned from exceptional tumour responses?: Review and perspectives.
    Mehra N; Lorente D; de Bono JS
    Curr Opin Oncol; 2015 May; 27(3):267-75. PubMed ID: 25811347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Precision oncology: A new era of cancer clinical trials.
    Renfro LA; An MW; Mandrekar SJ
    Cancer Lett; 2017 Feb; 387():121-126. PubMed ID: 26987624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How Imaging Biomarkers Can Inform Clinical Trials and Clinical Practice in the Era of Targeted Cancer Therapy.
    Farwell MD; Clark AS; Mankoff DA
    JAMA Oncol; 2015 Jul; 1(4):421-2. PubMed ID: 26181243
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 40.